Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$4.22
-0.16-3.65%
At close: -
$4.22
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Vanda Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:VNDA | Benzinga
Vanda Pharmaceuticals Inc has a consensus price target of $16.5 based on the ratings of 2 analysts. The high is $20 issued by HC Wainwright & Co. on May 7, 2025. The low is $13 issued by Cantor Fitzgerald on August 1, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on May 7, 2025, April 1, 2025, and February 18, 2025, respectively. With an average price target of $20 between HC Wainwright & Co., there's an implied 373.93% upside for Vanda Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Cantor Fitzgerald
1calculated from analyst ratings
Analyst Ratings for Vanda Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/07/2025 | Buy Now | 373.93% | HC Wainwright & Co. | Raghuram Selvaraju44% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 04/01/2025 | Buy Now | 373.93% | HC Wainwright & Co. | Raghuram Selvaraju44% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 02/18/2025 | Buy Now | 373.93% | HC Wainwright & Co. | Raghuram Selvaraju44% | $18 → $20 | Maintains | Buy | Get Alert |
| 02/04/2025 | Buy Now | 326.54% | HC Wainwright & Co. | Raghuram Selvaraju44% | $18 → $18 | Reiterates | Buy → Buy | Get Alert |
| 01/28/2025 | Buy Now | 326.54% | HC Wainwright & Co. | Raghuram Selvaraju44% | $18 → $18 | Reiterates | Buy → Buy | Get Alert |
| 01/21/2025 | Buy Now | 326.54% | HC Wainwright & Co. | Raghuram Selvaraju44% | $18 → $18 | Reiterates | Buy → Buy | Get Alert |
| 12/23/2024 | Buy Now | 326.54% | HC Wainwright & Co. | Raghuram Selvaraju44% | $18 → $18 | Reiterates | Buy → Buy | Get Alert |
| 10/31/2024 | Buy Now | 326.54% | HC Wainwright & Co. | Raghuram Selvaraju44% | → $18 | Initiates | → Buy | Get Alert |
| 08/01/2024 | Buy Now | 208.06% | Cantor Fitzgerald | Charles Duncan69% | $11 → $13 | Maintains | Overweight | Get Alert |
| 07/11/2024 | Buy Now | 160.66% | Cantor Fitzgerald | Charles Duncan69% | → $11 | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Vanda Pharmaceuticals (VNDA) stock?
The latest price target for Vanda Pharmaceuticals (NASDAQ:VNDA) was reported by HC Wainwright & Co. on May 7, 2025. The analyst firm set a price target for $20.00 expecting VNDA to rise to within 12 months (a possible 373.93% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Vanda Pharmaceuticals (VNDA)?
The latest analyst rating for Vanda Pharmaceuticals (NASDAQ:VNDA) was provided by HC Wainwright & Co., and Vanda Pharmaceuticals reiterated their buy rating.
When was the last upgrade for Vanda Pharmaceuticals (VNDA)?
There is no last upgrade for Vanda Pharmaceuticals
When was the last downgrade for Vanda Pharmaceuticals (VNDA)?
There is no last downgrade for Vanda Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Vanda Pharmaceuticals (VNDA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vanda Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vanda Pharmaceuticals was filed on May 7, 2025 so you should expect the next rating to be made available sometime around May 7, 2026.
Is the Analyst Rating Vanda Pharmaceuticals (VNDA) correct?
While ratings are subjective and will change, the latest Vanda Pharmaceuticals (VNDA) rating was a reiterated with a price target of $20.00 to $20.00. The current price Vanda Pharmaceuticals (VNDA) is trading at is $4.22, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
